Overview

The 'GLOW' protocol is a blend popular in wellness and aesthetic peptide circles, combining three separately researched compounds:

• BPC-157 -- a synthetic pentadecapeptide derived from a gastric protein that accelerates healing of tendon, ligament, muscle and gut tissue in animal models, in large part by promoting angiogenesis through VEGF upregulation (Chang et al., 2019; Brcic et al., 2009).
• TB-500 -- a synthetic fragment corresponding to the active region of thymosin beta-4, an actin-sequestering peptide that promotes cell migration, angiogenesis and wound repair (Philp et al., 2004).
• GHK-Cu -- the copper-binding tripeptide glycyl-L-histidyl-L-lysine, which drives tissue remodeling by stimulating collagen, elastin and glycosaminoglycan synthesis and supporting dermal fibroblasts (Pickart, 2008; Pickart et al., 2018).

The design rationale is mechanistic complementarity: BPC-157 and TB-500 both drive angiogenesis and cell migration needed for repair, while GHK-Cu supplies the matrix-building and skin-remodeling signal that gives the protocol its cosmetic 'glow' reputation.

Typical stack dosing (research-community practice, not clinically validated): commonly a once-daily subcutaneous injection providing roughly BPC-157 250-500 mcg, TB-500 250-500 mcg, and GHK-Cu 1-2 mg, often run in cycles of several weeks. These amounts are extrapolated from the component peptides' preclinical literature and community protocols rather than from trials of the blend; none of these peptides is FDA-approved, and human safety/efficacy data for the combination are lacking.

Mechanism of Action

The angiogenic and migratory actions of BPC-157 and TB-500 are complementary: BPC-157 works largely through the VEGFR2-Akt-eNOS/nitric-oxide axis to modulate blood-vessel formation during healing, while thymosin beta-4's LKKTET actin-binding domain drives endothelial and progenitor-cell migration. GHK-Cu then supplies the remodeling signal, increasing dermal fibroblast collagen/elastin output and supporting nerve and vessel outgrowth. The combined effect proposed by the protocol is faster tissue repair with improved skin and connective-tissue quality, though this synergy is inferred from single-agent data.

Reconstitution Calculator

Safety Profile

Safety Profile: Glow Protocol

Common Side Effects

• Side effects depend on the specific components included in the protocol formulation
• Mild gastrointestinal upset (nausea, bloating) from combined oral supplements
• Skin flushing or warmth, particularly with niacin-containing variants
• Headache during initial adaptation period
• Mild changes in urination patterns depending on ingredients

Serious Adverse Effects

• Potential for adverse interactions between multiple active compounds in the blend
• Allergic reactions to any component ingredient (rash, angioedema, anaphylaxis in rare cases)
• Liver or kidney stress from polypharmacy if protocol includes multiple hepatically metabolized compounds
• Hormonal disruption if protocol includes endocrine-active peptides or compounds

Contraindications

• Known allergy or hypersensitivity to any component of the protocol
• Pregnancy and lactation (insufficient safety data for combination protocols)
• Active liver or kidney disease
• Individuals currently on immunosuppressive therapy
• Minors under 18 years of age

Drug Interactions

• Interactions are component-dependent; review each individual ingredient
• Combined antioxidant blends may interfere with chemotherapy or radiation therapy
• Compounds with anticoagulant properties may potentiate blood thinners
• Potential for CYP450 enzyme modulation affecting prescription drug metabolism
• Supplements affecting blood glucose may interact with diabetes medications

Population-Specific Considerations

• Pregnancy/Lactation: Contraindicated due to lack of safety data on combined formulation
• Children/Adolescents: Not recommended; safety and efficacy not established
• Elderly: Start with reduced component doses; monitor organ function regularly
• Immunocompromised: Use with extreme caution; consult healthcare provider
• Chronic disease: Consult physician before starting any multi-compound protocol

Pharmacokinetic Profile